Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.
Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.
复制标题
通过使用电离辐射上调抗体靶标，扩大单克隆抗体治疗癌症的使用。
DOI：
10.1038/bjc.2014.79
复制
发表时间：
2014
影响因子：
8.8
通讯作者：
Hodge,JW
中科院分区：
文献类型：
--
作者：
Wattenberg,MM;Kwilas,AR;Gameiro,SR;Dicker,AP;Hodge,JW
Background:Monoclonal antibody (mAb) therapy for the treatment of solid and haematologic malignancies has shown poor response rates as a monotherapy. Furthermore, its use is limited to tumours expressing certain molecular targets. It has been shown that single-dose radiation can induce immunogenic modulation that is characterised by cell-surface phenotypic changes leading to augmented tumour cell/cytotoxic T-cell interaction.Methods:We examined radiation’s ability to upregulate mAb therapy targets. We also used radiation to sensitise tumour cells to antibody-dependent cell-mediated cytotoxicity (ADCC).Results:Radiation significantly increased cell-surface and total protein expression of mAb targets HER2, EGFR, and CD20. Focusing on HER2, targeted by trastuzumab, we observed significant upregulation of HER2 following radiation of 3 out of 3 breast cancer cell lines, one of which was triple negative, as well as in residential stem-cell populations. HER2 upregulation was sustained up to 96 h following radiation exposure and was largely dependent on intracellular reactive oxygen species. Improved ADCC and sensitisation to the antiproliferative effects of trastuzumab demonstrated the functional significance of radiation-induced HER2 upregulation.Conclusions:We show that single-dose radiation enhances mAb therapy. These findings highlight a mechanism for combining radiation with immunotherapy and expand the patient population that can be treated with targeted therapy.
